{"contentid": 488133, "importid": NaN, "name": "Recordati reports positive results from Phase III Isturisa trial in Cushing\u00e2\u0080\u0099s disease", "introduction": "Italian drugmaker Recordati has presented positive results from the Phase III LINC 4 study of Isturisa (osilodrostat) at the Endocrine Society\u00e2\u0080\u0099s Annual Meeting.", "content": "<p>Italian drugmaker Recordati (RECI: MI) has presented positive results from the Phase III LINC 4 study of Isturisa (osilodrostat) at the Endocrine Society&rsquo;s Annual Meeting.</p>\n<p>Isturisa is indicated in the European Union and the USA for the treatment of adult patients with endogenous Cushing&rsquo;s syndrome and Cushing&rsquo;s disease, respectively.</p>\n<p>Cushing&rsquo;s syndrome is a rare disorder caused by chronic exposure to excess levels of cortisol from either an exogenous or an endogenous source.</p>\n<p>Results from the trial, which is the first study in patients with Cushing&rsquo;s disease to include an upfront, double-blind, randomized, placebo-controlled period, demonstrated that Isturisa provided rapid and sustained normalization of mean urinary free cortisol (mUFC) levels.</p>\n<p>Normalizing mUFC levels represents an important treatment goal that can potentially reduce morbidity, improve quality of life and restore the life expectancy of patients with Cushing&rsquo;s disease towards that of the general population.</p>\n<p>Isturisa was well tolerated in LINC 4, further supporting the manageable safety profile established in previous studies.</p>\n<p>M&ocirc;nica Gadelha, professor of endocrinology at Universidade Federal do Rio de Janeiro, said: &ldquo;The exciting data presented today further emphasize the efficacy and tolerability of Isturisa and build on the positive findings from the LINC 3 pivotal study.</p>\n<p>&ldquo;Importantly, treatment with Isturisa was effective in normalizing mUFC levels in the majority of patients from the start of treatment, improved clinical signs of hypercortisolism and cardiovascular-related risk factors, and was well tolerated.&rdquo;</p>", "date": "2021-03-23 17:41:00", "meta_title": NaN, "meta_keywords": "Isturisa, results, positive, Recordati, Phase, disease, Cushings, study, LINC, presented, levels, patients, trial, treatment, Cushing\u00e2\u0080\u0099s, reports, Italian", "meta_description": "Family-owned Italian drugmaker Recordati has presented positive results from the Phase III LINC 4 study of Isturisa (osilodrostat) at the Endocrine Society\u00e2\u0080\u0099s An", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-23 17:30:26", "updated": "2021-03-23 18:57:07", "access": NaN, "url": "https://www.thepharmaletter.com/article/recordati-reports-positive-results-from-phase-iii-isturisa-trial-in-cushing-s-disease", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "recordati-large.jpg", "image2id": "recordati-small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Endocrinology, Rare diseases", "topic_tag": "Drug Trial, Research", "geography_tag": "Italy", "company_tag": "Recordati", "drug_tag": "Isturisa", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-23 17:41:00"}